(572bo) siRNA Delivery by RONDELTM, a Cyclodextrin-Polymer Based Delivery System: From Benchtop to the Clinics Conference: AIChE Annual MeetingYear: 2008Proceeding: 2008 AIChE Annual MeetingGroup: Food, Pharmaceutical & Bioengineering DivisionSession: Poster Session: Engineering Fundamentals in Life Sciences Time: Wednesday, November 19, 2008 - 6:00pm-8:30pm Authors: Chuang, H. F., Calando Pharmaceuticals Heidel, J. D., Calando Pharmaceuticals Liu, J. Y., Calando Pharmaceuticals Zeidan, R. K., Calando Pharmaceuticals Liang, Y., Calando Pharmaceuticals Rele, S., Calando Pharmaceuticals Davis, M. E., California Institute of Technology Calando Pharmaceuticals is developing a proprietary, targeted siRNA delivery platform, RONDEL? (RNAi/oligonucleotide delivery), which formulates therapeutic siRNA into targeted nanoparticles. CALAA-01, Calando's lead nanoparticle drug candidate, contains an siRNA targeting the M2 subunit of ribonucleotide reductase (RRM2) for applications in cancer. Extensive characterizations have been performed on the physicochemical properties, in vitro efficacy, and in vivo safety of these nanoparticle formulations. CALAA-01 is currently in a Phase I human clinical trial, representing the first targeted systemic siRNA delivery in the clinics and the only clinical stage RNAi therapeutic oncology program. As a demonstration of the versatility of the RONDEL? platform, Calando is also developing a second candidate, CALAA-02, which contains an siRNA targeting the hypoxia inducible factor-2 alpha (HIF-2α), for applications in cancer as well. CALAA-02 is currently in pre-clinical development.